What happens when you take tacrolimus with st. john's wort?
Tacrolimus is a calcineurin inhibitor used after kidney, liver, heart, and other organ transplants to prevent rejection, and at lower doses for some autoimmune and dermatologic conditions. Like cyclosporine, it is a substrate of intestinal and hepatic CYP3A4 and of the P-glycoprotein efflux pump. The therapeutic window is narrow, with trough targets often in the 5-15 ng/mL range and small percentage changes producing meaningful clinical effects.
St. John's wort contains hyperforin, a potent activator of the pregnane X receptor (PXR). PXR activation upregulates CYP3A4 and P-glycoprotein expression in the gut and liver. Within one to two weeks, the body clears tacrolimus much faster, so blood levels fall and the immunosuppressive effect weakens.
The reverse direction is equally important: stopping St. John's wort abruptly causes enzyme levels to return to baseline over one to two weeks. If the tacrolimus dose was raised during induction, levels can rebound sharply, sometimes into the toxic range. A published case from Bolley and colleagues described a renal transplant recipient whose tacrolimus nephrotoxicity was unmasked when the underlying CYP3A4 induction from St. John's wort wore off and concentrations climbed beyond the therapeutic window.
Why is this important?
Tacrolimus exposure is the single biggest determinant of both rejection risk and toxicity in many transplant patients. Subtherapeutic troughs allow acute cellular rejection, which damages the graft and may require pulse steroids and intensified immunosuppression. Supratherapeutic troughs cause nephrotoxicity, neurotoxicity (tremor, headache, confusion, in rare cases seizures), new-onset diabetes after transplant, and hypertension.
St. John's wort combines both risks. While the patient is taking the herb, troughs drift down and rejection becomes possible. If clinicians escalate the dose to compensate and then the herb is discontinued, troughs surge and toxicity becomes likely. The unpredictability is the danger: blood level changes happen on a 1-2 week timescale that does not match typical clinic follow-up intervals.
Modern extended-release tacrolimus formulations are not immune to the interaction. A recent clinical pharmacology study showed that prolonged-release tacrolimus is still significantly affected by St. John's wort, though the effect on Cmax may differ from immediate-release formulations.
What should you do?
Treat St. John's wort as off-limits while on tacrolimus. Avoid capsules, tinctures, teas, and multi-herb blends labeled for low mood, sleep, anxiety, or menopause that may contain hypericum. If you are starting tacrolimus and have been taking St. John's wort, tell your transplant team before your first dose so they can adjust monitoring during the transition.
If you discover you have been taking St. John's wort while on tacrolimus, stop the herb and call your prescriber the same day. Do not adjust your tacrolimus dose on your own; the team will likely schedule extra trough checks at days 3-5 and then weekly for several weeks, with dose adjustments matched to the changing enzyme activity.
For low mood symptoms, several conventional antidepressants are compatible with tacrolimus when chosen carefully. Some SSRIs and SNRIs inhibit CYP3A4 mildly and may need a small tacrolimus dose adjustment, but they do not produce the chaotic two-way swings that St. John's wort causes. Discuss alternatives with your transplant psychiatrist or primary clinician rather than self-treating.
Which specific products are affected?
The interaction applies to all tacrolimus products: Prograf (immediate-release capsules), Astagraf XL and Envarsus XR (extended-release), and the generic immediate-release equivalents. Topical tacrolimus ointment (Protopic) has minimal systemic absorption, but if you are on oral tacrolimus alongside it, the systemic route is what matters.
On the herb side, all hypericum perforatum extracts induce CYP3A4 to some degree, and extracts standardized to hyperforin (often 3-5%) or hypericin (often 0.3%) are particularly potent. Read labels on multi-ingredient supplements; St. John's wort is often combined with passionflower, valerian, kava, or 5-HTP in mood blends without being highlighted on the product front.
Be cautious with topical and homeopathic St. John's wort products. Topical preparations for nerve pain or bruising contain low concentrations and are unlikely to cause systemic induction, but skin patches and salves with red oil extracts can deliver more than expected. Homeopathic dilutions (30C and higher) contain essentially no active compound and are unlikely to interact, but lower potencies (1X-6X) may.
The bottom line
St. John's wort and tacrolimus should not be combined. The herb induces CYP3A4 and P-glycoprotein, causing tacrolimus levels to drop and risking rejection; stopping the herb abruptly can swing levels back into the toxic range and unmask nephrotoxicity. If you take tacrolimus, avoid St. John's wort entirely, and if you have been combining them, contact your transplant team right away for accelerated monitoring.